IL1B and pustular psoriasis: Recently, it was reported that patients with severe pustular psoriasis showed substantial clinical response to anti-IL-1β gevokizumab and canakinumab (6, 7), suggesting a critical involvement of IL-1β in GPP pathogenesis.